A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor.

We observed that the novel RANKL indeed blocks RANKL via LGR4 signaling and generates anti-RANKL antibodies, demonstrating an innovative strategy in the development of general immunotherapy.